Breaking News
Get 50% Off 0
💎 Bargain Hunter: Undervalued stocks with massive upside potential
Get the list
Close

Chiome Bioscience Inc (4583)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
143.0 +1.0    +0.70%
07:30:29 - Closed. Currency in JPY
Type:  Equity
Market:  Japan
ISIN:  JP3205350006 
  • Volume: 647,000
  • Bid/Ask: 141.0 / 143.0
  • Day's Range: 140.0 - 143.0
Chiome Bioscience 143.0 +1.0 +0.70%

Chiome Bioscience Inc Company Profile

 
Get an in-depth profile of Chiome Bioscience Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

53

Equity Type

ORD

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. The company also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. Its product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). The company’s product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. It serves universities, research institutions, diagnostic companies, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.

Contact Information

Address Sumitomo Fudosan Nishi-shinjuku Bldg.No.6 3-12-1 Honmachi
Shibuya-ku Tokyo, 151-0071
Japan
Phone 81 3 6383 3561
Fax -

Top Executives

Name Age Since Title
Yoshiyuki Yamakawa 63 2020 Independent Outside Director
Akiyuki Furuya 80 - Independent Outside Director
Masamichi Koike 63 2023 President, CEO & Executive Director
Niro Sakamoto 65 2021 Independent Outside Director
Hiroyuki Kawai 71 2025 Independent Outside Director
Teruyo Taoka 56 2020 GM of Development Division & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4583 Comments

Write your thoughts about Chiome Bioscience Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email